CompoundIQ

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

SteroidAdvancedHigh Risk

Furazabol

Also known as: Miotolan, Furazabol THP

Furazabol is an anabolic steroid structurally related to stanozolol, with a furazan ring replacing the pyrazole ring. It was briefly marketed in Japan under the brand name Miotolan for treating hyperlipidemia. It is notable for reportedly having a favorable effect on lipid profiles, which is unusual among oral steroids, though this claim is disputed.

Evidence22/100 — Minimal

Risk Level

High Risk

Difficulty

Advanced
CAS Number1239-29-8
Molecular FormulaC20H30N2O2
ClassSteroid
CategoryUnderground Steroids

Mechanism of Action

A DHT-derived steroid with a furazan (1,2,5-oxadiazole) ring fused to the A-ring. Binds androgen receptors similarly to stanozolol. Reportedly has lipid-lowering properties, possibly through effects on hepatic lipase or cholesterol metabolism, though evidence is limited. Does not aromatize. Has moderate anabolic and low androgenic activity.

Dosing Research

Japanese medical dosing was 1-2 mg per day for lipid management. Performance enhancement doses in underground use ranged from 5-20 mg per day. Cycles of 4-8 weeks. Available in THP ether prodrug form in the supplement market. Limited dosing guidance available.

Side Effects & Risks

Hepatotoxicity expected for the methylated version, though potentially less than stanozolol. Reports of favorable lipid effects are unconfirmed and should not be assumed. HPTA suppression. Androgenic side effects possible. Joint dryness similar to stanozolol. Very limited modern safety data.

Research Studies

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

Send Feedback

Help us improve CompoundIQ